{"id":2505,"date":"2024-01-17T10:08:50","date_gmt":"2024-01-17T10:08:50","guid":{"rendered":"https:\/\/curateqbio.com\/?p=2505"},"modified":"2024-01-22T10:28:08","modified_gmt":"2024-01-22T10:28:08","slug":"curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india","status":"publish","type":"post","link":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/","title":{"rendered":"CuraTeQ Biologics\u2019 Trastuzumab Biosimilar receives recommendation for marketing authorization in India"},"content":{"rendered":"\r\n<section id=\"post-content-block_64ccb899d4420\" class=\"post-content\">\r\n    <div class=\"text-container\">\r\n        <h3 class=\"article_desc\">Aurobindo Pharma Ltd&#8217;s wholly-owned subsidiary, CuraTeQ Biologics Private Ltd, on Wednesday, January 17, received marketing authorisation from the Central Drugs Standard Control Organization (CDSCO) for biosimilar trastuzumab.<\/h3>\n<p><strong>In a stock exchange filing, Aurobindo Pharma said that CuraTeQ Biologics received a recommendation for grant of marketing authorisation of biosimilar trastuzumab from the Subject Experts Committee (SEC) of CDSCO, the apex drug regulator in India.<\/strong><\/p>\n<p>Trastuzumab biosimilar is a humanised monoclonal antibody that is used in the treatment of metastatic breast cancer and early breast cancer.<\/p>\n<div class=\"jsx-4003967465 nart-para \">This monoclonal antibody is supplied in single dose glass vials that contain lyophilized powder in the dosages of 150 mg and 420 mg as concentrate for solution for infusion, Aurobindo Pharma informed the bourses.<\/div>\n<div class=\"jsx-4003967465 nart-para \"><\/div>\n<div class=\"jsx-4003967465 nart-para \">CuraTeQ was asked to submit Phase IV clinical trial protocol to CDSCO within three months of receiving the marketing authorisation.<\/div>\n<p>Article excerpt reposted from <a href=\"https:\/\/www.cnbctv18.com\/market\/aurobindo-pharma-share-price-subsidiary-receives-cdsco-nod-for-breast-cancer-treatment-drug-18822331.htm\" target=\"_blank\" rel=\"noopener\"><strong>cnbctv18.com<\/strong><\/a><\/p>\n    <\/div>\r\n<\/section>\r\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":2506,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[7],"tags":[12,13,14,15,27,35],"class_list":["post-2505","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-release","tag-curateq-biologics","tag-trastuzumab","tag-biosimilars","tag-breast-cancer","tag-biologics","tag-marketing-authorization"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>CuraTeQ Biologics\u2019 Trastuzumab Biosimilar receives recommendation for marketing authorization in India - CuraTeQ Biologics<\/title>\n<meta name=\"description\" content=\"CuraTeQ Biologics&#039; Trastuzumab biosimilar receives recommendation for marketing authorization in India from Subject Expert Committee - CDSCO.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CuraTeQ Biologics\u2019 Trastuzumab Biosimilar receives recommendation for marketing authorization in India - CuraTeQ Biologics\" \/>\n<meta property=\"og:description\" content=\"CuraTeQ Biologics&#039; Trastuzumab biosimilar receives recommendation for marketing authorization in India from Subject Expert Committee - CDSCO.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/\" \/>\n<meta property=\"og:site_name\" content=\"CuraTeQ Biologics\" \/>\n<meta property=\"article:published_time\" content=\"2024-01-17T10:08:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-22T10:28:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/curateqbio.com\/wp-content\/uploads\/2024\/01\/infrastructure-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1438\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"curateq-admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"curateq-admin\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/\",\"url\":\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/\",\"name\":\"CuraTeQ Biologics\u2019 Trastuzumab Biosimilar receives recommendation for marketing authorization in India - CuraTeQ Biologics\",\"isPartOf\":{\"@id\":\"https:\/\/curateqbio.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/curateqbio.com\/wp-content\/uploads\/2024\/01\/infrastructure-scaled.jpg\",\"datePublished\":\"2024-01-17T10:08:50+00:00\",\"dateModified\":\"2024-01-22T10:28:08+00:00\",\"author\":{\"@id\":\"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235\"},\"description\":\"CuraTeQ Biologics' Trastuzumab biosimilar receives recommendation for marketing authorization in India from Subject Expert Committee - CDSCO.\",\"breadcrumb\":{\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#primaryimage\",\"url\":\"https:\/\/curateqbio.com\/wp-content\/uploads\/2024\/01\/infrastructure-scaled.jpg\",\"contentUrl\":\"https:\/\/curateqbio.com\/wp-content\/uploads\/2024\/01\/infrastructure-scaled.jpg\",\"width\":2560,\"height\":1438,\"caption\":\"CuraTeQ Biologics receives EMA GMP certificate.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/curateqbio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CuraTeQ Biologics\u2019 Trastuzumab Biosimilar receives recommendation for marketing authorization in India\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/curateqbio.com\/#website\",\"url\":\"https:\/\/curateqbio.com\/\",\"name\":\"CuraTeQ Biologics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/curateqbio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235\",\"name\":\"curateq-admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/curateqbio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g\",\"caption\":\"curateq-admin\"},\"sameAs\":[\"http:\/\/curateq.local\"],\"url\":\"https:\/\/curateqbio.com\/author\/curateq-admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CuraTeQ Biologics\u2019 Trastuzumab Biosimilar receives recommendation for marketing authorization in India - CuraTeQ Biologics","description":"CuraTeQ Biologics' Trastuzumab biosimilar receives recommendation for marketing authorization in India from Subject Expert Committee - CDSCO.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/","og_locale":"en_US","og_type":"article","og_title":"CuraTeQ Biologics\u2019 Trastuzumab Biosimilar receives recommendation for marketing authorization in India - CuraTeQ Biologics","og_description":"CuraTeQ Biologics' Trastuzumab biosimilar receives recommendation for marketing authorization in India from Subject Expert Committee - CDSCO.","og_url":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/","og_site_name":"CuraTeQ Biologics","article_published_time":"2024-01-17T10:08:50+00:00","article_modified_time":"2024-01-22T10:28:08+00:00","og_image":[{"width":2560,"height":1438,"url":"https:\/\/curateqbio.com\/wp-content\/uploads\/2024\/01\/infrastructure-scaled.jpg","type":"image\/jpeg"}],"author":"curateq-admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"curateq-admin"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/","url":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/","name":"CuraTeQ Biologics\u2019 Trastuzumab Biosimilar receives recommendation for marketing authorization in India - CuraTeQ Biologics","isPartOf":{"@id":"https:\/\/curateqbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#primaryimage"},"image":{"@id":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#primaryimage"},"thumbnailUrl":"https:\/\/curateqbio.com\/wp-content\/uploads\/2024\/01\/infrastructure-scaled.jpg","datePublished":"2024-01-17T10:08:50+00:00","dateModified":"2024-01-22T10:28:08+00:00","author":{"@id":"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235"},"description":"CuraTeQ Biologics' Trastuzumab biosimilar receives recommendation for marketing authorization in India from Subject Expert Committee - CDSCO.","breadcrumb":{"@id":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#primaryimage","url":"https:\/\/curateqbio.com\/wp-content\/uploads\/2024\/01\/infrastructure-scaled.jpg","contentUrl":"https:\/\/curateqbio.com\/wp-content\/uploads\/2024\/01\/infrastructure-scaled.jpg","width":2560,"height":1438,"caption":"CuraTeQ Biologics receives EMA GMP certificate."},{"@type":"BreadcrumbList","@id":"https:\/\/curateqbio.com\/curateq-biologics-trastuzumab-biosimilar-receives-recommendation-for-marketing-authorization-in-india\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/curateqbio.com\/"},{"@type":"ListItem","position":2,"name":"CuraTeQ Biologics\u2019 Trastuzumab Biosimilar receives recommendation for marketing authorization in India"}]},{"@type":"WebSite","@id":"https:\/\/curateqbio.com\/#website","url":"https:\/\/curateqbio.com\/","name":"CuraTeQ Biologics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/curateqbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/curateqbio.com\/#\/schema\/person\/ada896a037198d1a34fed5ca62571235","name":"curateq-admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/curateqbio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1f5bfa143bdcee393defa3cc5e4dd1b8?s=96&d=mm&r=g","caption":"curateq-admin"},"sameAs":["http:\/\/curateq.local"],"url":"https:\/\/curateqbio.com\/author\/curateq-admin\/"}]}},"_links":{"self":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts\/2505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/comments?post=2505"}],"version-history":[{"count":5,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts\/2505\/revisions"}],"predecessor-version":[{"id":2511,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/posts\/2505\/revisions\/2511"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/media\/2506"}],"wp:attachment":[{"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/media?parent=2505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/categories?post=2505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/curateqbio.com\/wp-json\/wp\/v2\/tags?post=2505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}